Sabinsa, the globally renowned research-oriented supplier known for its sustainable and innovative nutraceutical and cosmeceutical ingredients, will highlight LactoSpore™ Weizmannia coagulans at the Expanding the Lineup: Next Probiotics and Supplement Spring Symposium hosted by the Korean Society for Lactic Acid Bacteria and Probiotics in Seoul, Korea on May 24, 2024.
“LactoSpore is a successful product worldwide, but especially in markets such as South Korea where customers have a higher understanding of probiotics,” said Mr. Shaheen Majeed, Global Managing Director and CEO of Sabinsa. "Because of its efficacy, safety, and flexibility in a range of manufacturing conditions, LactoSpore is formulated into numerous product categories from supplements to functional foods.”
Dr. Sivakumar Arumugam, Vice President, Biotechnology, Sami-Sabinsa Group, will deliver a presentation on “Safety and efficacy of Weizmannia coagulans, a spore forming and shelf-stable probiotic, for gut health and beyond” in the International Conference Room, Konkuk University, Seoul, on May 24, 4:30 p.m. to 5:00 p.m.
Sabinsa’s LactoSpore Weizmannia coagulans, MTCC 5856 (previously known as Bacillus coagulans), has been a popular probiotic on the global market since the early 1990’s. Its safety and efficacy demonstrated by clinical studies, coupled with its stability at room temperature and ability to withstand challenging manufacturing conditions, have made it a probiotic of choice among dietary supplement and functional food manufacturers worldwide.
LactoSpore’s lactic acid-producing bacteria form spores, or seeds. When activated in the GI Tract, the spores germinate and proliferate in the intestine, producing the favored form of lactic acid that prevents the growth of pathogens, helping maintain a balanced gut microbiome. These spores are extremely stable, remaining dormant until they arrive safely in the intestinal tract to colonize and grow. Spore forming allows Weizmannia coagulans to survive at both high and low temperatures, and resist the harsh human gastric environment, enabling delivery under a wide range of conditions and through a broad spectrum of systems.
The most recent recognition of LactoSpore’s superiority was the 2023 Technology Innovation Award at the 3rd Food Formula Innovation Show held in China. Sabinsa’s LactoSpore currently holds 38 granted active patents across the globe.
For more information, visit www.sabinsa.co.kr and www.sami-sabinsagroup.com.
Note: LactoSpore™, a Trademark of Sabinsa Korea Corporation.
